Targeted Agents in Preclinical and Early Clinical Development for the Treatment of Cancer Bone Metastases

References

• Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584–593.
   PubMed Web of Science ®Google Scholar
• Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11:411–425.
   PubMed Web of Science ®Google Scholar
• Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243s– 6249s.
   PubMed Web of Science ®Google Scholar
• Wong MH, Pavlakis N. Optimal management of bone metastases in breast cancer patients. Breast Cancer Targets Ther. 2011;3:35.
   PubMedGoogle Scholar
• Sun L, Yu S. Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis. Am J Clin Oncol. 2013;36:399–403.
   PubMed Web of Science ®Google Scholar
• Coleman R, Gnant M, Morgan G, et al. Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst. 2012;104:1059–1067.
   PubMed Web of Science ®Google Scholar
• Costa AG, Cusano NE, Silva BC, et al. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol. 2011;7:447–456.
   PubMed Web of Science ®Google Scholar
• Saftig P, Hunziker E, Wehmeyer O, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A. 1998;95:13453–13458.
   PubMed Web of Science ®Google Scholar
• Gelb BD, Shi G-P, Chapman HA, et al. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 1996;273:1236–1238.
   PubMed Web of Science ®Google Scholar
• Le Gall C, Bellahcene A, Bonnelye E, et al. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res. 2007;67:9894–9902.
   PubMed Web of Science ®Google Scholar
• Littlewood-Evans AJ, Bilbe G, Bowler WB, et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 1997;57:5386–5390.
   PubMed Web of Science ®Google Scholar
• Brubaker KD, Vessella RL, True LD, et al. Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res. 2003;18:222–230.
   PubMed Web of Science ®Google Scholar
• Chapurlat RD. Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women. Ther Adv Musculoskelet Dis. 2015;7:103–109.
   PubMed Web of Science ®Google Scholar
• Jensen AB, Wynne C, Ramirez G, et al. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer. 2010;10:452–458.
   PubMed Web of Science ®Google Scholar
• Mayer EL, Krop IE. Advances in targeting Src in the treatment of breast cancer and other solid malignancies. Clin Cancer Res. 2010;16:3526–3532.
   PubMed Web of Science ®Google Scholar
• Zhang S, Yu D. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci. 2012;33:122–128.
   PubMed Web of Science ®Google Scholar
• Soriano P, Montgomery C, Geske R, et al. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell. 1991;64:693–702.
   PubMed Web of Science ®Google Scholar
• Boyce BF, Yoneda T, Lowe C, et al. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest. 1992;90:1622–1627.
   PubMed Web of Science ®Google Scholar
• Myoui A, Nishimura R, Williams PJ, et al. C-src tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res. 2003;63:5028–5033.
   PubMed Web of Science ®Google Scholar
• Zhang XHF, Wang Q, Gerald W, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell. 2009;16:67–78.
   PubMed Web of Science ®Google Scholar
• Koreckij T, Nguyen H, Brown LG, et al. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer. 2009;101:263–268.
   PubMed Web of Science ®Google Scholar
• Rabbani SA, Valentino M-L, Arakelian A, et al. SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. Mol Cancer Ther. 2010;9:1147–1157.
   PubMed Web of Science ®Google Scholar
• Yang JC, Bai L, Yap S, et al. Effect of the specific src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model. Mol Cancer Ther. 2010;9:1629–1637.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Miyazaki M, Okamoto I, et al. Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors. Cancer Sci. 2011;102:2058–2064.
   PubMed Web of Science ®Google Scholar
• Yu EY, Wilding G, Posadas E, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2009;15:7421–7428.
   PubMed Web of Science ®Google Scholar
• Araujo JC, Trudel GC, Saad F, et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 2013;14:1307–1316.
   PubMed Web of Science ®Google Scholar
• Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res. 2010;339:269–280.
   PubMed Web of Science ®Google Scholar
• Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9–22.
   PubMed Web of Science ®Google Scholar
• Schneider JG, Amend SR, Weilbaecher KN. Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. Bone. 2011;48:54–65.
   PubMed Web of Science ®Google Scholar
• Xu F, Teitelbaum SL. Osteoclasts: new insights. Bone Res. 2013;1:11–26.
   PubMed Web of Science ®Google Scholar
• Brooks P, Clark R, Cheresh D. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264:569–571.
   PubMed Web of Science ®Google Scholar
• Pécheur I, Peyruchaud O, Serre CM, et al. Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. Faseb J. 2002;16:1266–1268.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Bachelier R, Treilleux I, et al. Tumor αvβ3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res. 2007;67:5821–5830.
   PubMed Web of Science ®Google Scholar
• Bakewell SJ, Nestor P, Prasad S, et al. Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci U S A. 2003;100:14205–14210.
   PubMed Web of Science ®Google Scholar
• Mulgrew K, Kinneer K, Yao X-T, et al. Direct targeting of αvβ3 integrin on tumor cells with a monoclonal antibody, Abegrin. Mol Cancer Ther. 2006;5:3122–3129.
   PubMed Web of Science ®Google Scholar
• Gramoun A, Shorey S, Bashutski JD, et al. Effects of Vitaxin, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro. J Cell Biochem. 2007;102:341–352.
   PubMed Web of Science ®Google Scholar
• Bretschi M, Merz M, Komljenovic D, et al. Cilengitide inhibits metastatic bone colonization in a nude rat model. Oncol Rep. 2011;26:843–851.
   PubMed Web of Science ®Google Scholar
• Forgac M. Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nat Rev Mol Cell Biol. 2007;8:917–929.
   PubMed Web of Science ®Google Scholar
• Keeling DJ, Herslof M, Ryberg B, et al. Vacuolar H+-ATPases. Targets for drug discovery? Ann N Y Acad Sci. 1997;834:600–608.
   PubMed Web of Science ®Google Scholar
• Li YP, Chen W, Liang Y, et al. Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. Nat Genet. 1999;23:447–451.
   PubMed Web of Science ®Google Scholar
• Visentin L, Dodds RA, Valente M, et al. A selective inhibitor of the osteoclastic V-H+-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats. J Clin Invest. 2000;106:309–318.
   PubMed Web of Science ®Google Scholar
• Niikura K, Takeshita N, Takano M. A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application. J Bone Miner Res. 2005;20:1579–1588.
   PubMed Web of Science ®Google Scholar
• Nishisho T, Hata K, Nakanishi M, et al. The a3 isoform vacuolar type H+-ATPase promotes distant metastasis in the mouse B16 melanoma cells. Mol Cancer Res. 2011;9:845–855.
   PubMed Web of Science ®Google Scholar
• Capecci J, Forgac M. The function of vacuolar ATPase (V-ATPase) a subunit isoforms in invasiveness of MCF10a and MCF10CA1a human breast cancer cells. J Biol Chem. 2013;288:32731–32741.
   PubMed Web of Science ®Google Scholar
• Terpos E, Christoulas D. Effects of proteasome inhibitors on bone cancer. Bonekey Rep. 2013;2:395.
   PubMedGoogle Scholar
• Mohty M, Malard F, Mohty B, et al. The effects of bortezomib on bone disease in patients with multiple myeloma. Cancer. 2014;120:618–623.
   PubMed Web of Science ®Google Scholar
• Zavrski I, Krebbel H, Wildemann B, et al. Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem Biophys Res Commun. 2005;333:200–205.
   PubMed Web of Science ®Google Scholar
• Garrett IR, Chen D, Gutierrez G, et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest. 2003;111:1771–1782.
   PubMed Web of Science ®Google Scholar
• Bellido T, Ali AA, Plotkin LI, et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem. 2003;278:50259–50272.
   PubMed Web of Science ®Google Scholar
• Qiang Y-W, Hu B, Chen Y, et al. Bortezomib induces osteoblast differentiation via Wnt-independent activation of -catenin/TCF signaling. Blood. 2009;113:4319–4330.
   PubMed Web of Science ®Google Scholar
• Oyajobi BO, Garrett IR, Gupta A, et al. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol. 2007;139:434–438.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071–3076.
   PubMed Web of Science ®Google Scholar
• Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res. 2001;7:1419–1428.
   PubMed Web of Science ®Google Scholar
• Whang PG, Gamradt SC, Gates JJ, et al. Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases. Prostate Cancer Prostatic Dis. 2005;8:327–334.
   PubMed Web of Science ®Google Scholar
• Jones MD, Liu JC, Barthel TK, et al. A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes. Clin Cancer Res. 2010;16:4978–4989.
   PubMed Web of Science ®Google Scholar
• Yang CH, Gonzalez-Angulo AM, Reuben JM, et al. Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol. 2006;17:813–817.
   PubMed Web of Science ®Google Scholar
• Pal A, Young MA, Donato NJ. Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer. Cancer Res. 2014;74:4955–4966.
   PubMed Web of Science ®Google Scholar
• Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006;6:729–734.
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 2014;4:1–11.
   PubMedGoogle Scholar
• Kneissel M, Luong-Nguyen N-H, Baptist M, et al. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone. 2004;35:1144–1156.
   PubMed Web of Science ®Google Scholar
• Okui T, Shimo T, Fukazawa T, et al. Antitumor effect of temsirolimus against oral squamous cell carcinoma associated with bone destruction. Mol Cancer Ther. 2010;9:2960–2969.
   PubMed Web of Science ®Google Scholar
• Hussein O, Tiedemann K, Murshed M, et al. Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases. Cancer Lett. 2012;314:176–184.
   PubMed Web of Science ®Google Scholar
• Morgan TM, Pitts TEM, Gross TS, et al. RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate. 2008;68:861–871.
   PubMed Web of Science ®Google Scholar
• Gnant M, Baselga J, Rugo HS, et al. Effect of Everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J Natl Cancer Inst. 2013;105:654–663.
   PubMed Web of Science ®Google Scholar
• Ng JMY, Curran T. The Hedgehog’s tale: developing strategies for targeting cancer. Nat Rev Cancer. 2011;11:493–501.
   PubMed Web of Science ®Google Scholar
• Heller E, Hurchla MA, Xiang J, et al. Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. Cancer Res. 2012;72:897–907.
   PubMed Web of Science ®Google Scholar
• Yaccoby S, Wezeman MJ, Zangari M, et al. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica. 2006;91:192–199.
   PubMed Web of Science ®Google Scholar
• Krawetz R, Wu YE, Rancourt DE, et al. Osteoblasts suppress high bone turnover caused by osteolytic breast cancer in-vitro. Exp Cell Res. 2009;315:2333–2342.
   PubMed Web of Science ®Google Scholar
• Pennisi A, Ling W, Li X, et al. Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone. PLoS One. 2010;5:e15233.
   PubMed Web of Science ®Google Scholar
• Canalis E. Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches. Nat Rev Endocrinol. 2013;9:575–583.
   PubMed Web of Science ®Google Scholar
• Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11–26.
   PubMed Web of Science ®Google Scholar
• Tian E, Zhan F, Walker R, et al. The role of the Wnt-signalling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349:2483–2494.
   PubMed Web of Science ®Google Scholar
• Voorzanger-Rousselot N, Goehrig D, Journe F, et al. Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer. 2007;97:964–970.
   PubMed Web of Science ®Google Scholar
• Thudi NK, Martin CK, Murahari S, et al. Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases. Prostate. 2011;71:615–625.
   PubMed Web of Science ®Google Scholar
• Yaccoby S, Ling W, Zhan F, et al. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007;109:2106–2111.
   PubMed Web of Science ®Google Scholar
• Iyer SP, Beck JT, Stewart AK, et al. A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol. 2014;167:366–375.
   PubMed Web of Science ®Google Scholar
• Mendoza-Villanueva D, Zeef L, Shore P. Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin. Breast Cancer Res. 2011;13:R106.
   PubMed Web of Science ®Google Scholar
• McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370:412–420.
   PubMed Web of Science ®Google Scholar
• Leto G. Activin A and bone metastasis. J Cell Physiol. 2010;225:302–309.
   PubMed Web of Science ®Google Scholar
• Incorvaia L, Badalamenti G, Rini G, et al. MMP-2, MMP-9 and activin a blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Anticancer Res. 2007;27:1519–1525.
   PubMed Web of Science ®Google Scholar
• Terpos E, Kastritis E, Christoulas D, et al. Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. Ann Oncol. 2012;23:2681–2686.
   PubMed Web of Science ®Google Scholar
• Chantry AD, Heath D, Mulivor AW, et al. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J Bone Miner Res. 2010;25:2633–2646.
   PubMed Web of Science ®Google Scholar
• Abdulkadyrov KM, Salogub GN, Khuazheva NK, et al. Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol. 2014;165:814–823.
   PubMed Web of Science ®Google Scholar
• Rosanò L, Spinella F, Bagnato A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2013;13:637–651.
   PubMed Web of Science ®Google Scholar
• Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A. 2003;100:10954–10959.
   PubMed Web of Science ®Google Scholar
• Carducci MA, Saad F, Abrahamsson P-A, et al A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007;110:1959–1966.
   PubMed Web of Science ®Google Scholar
• Quinn DI, Tangen CM, Hussain M, et al. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013;14:893–900.
   PubMed Web of Science ®Google Scholar
• Lara PN, Ely B, Quinn DI, et al. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. J Natl Cancer Inst. 2014;106:dju013.
   PubMedGoogle Scholar
• Nelson JB, Fizazi K, Miller K, et al. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer. 2012;118:5709–5718.
   PubMed Web of Science ®Google Scholar
• Fizazi KS, Higano CS, Nelson JB, et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2013;31:1740–1747.
   PubMed Web of Science ®Google Scholar
• Ikushima H, Miyazono K. TGFβ signalling: a complex web in cancer progression. Nat Rev Cancer. 2010;10:415–424.
   PubMed Web of Science ®Google Scholar
• Korpal M, Yan J, Lu X, et al. Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med. 2009;15:960–966.
   PubMed Web of Science ®Google Scholar
• Juárez P, Guise TA. TGF-β in cancer and bone: implications for treatment of bone metastases. Bone. 2011;48:23–29.
   PubMed Web of Science ®Google Scholar
• Buijs JT, Stayrook KR, Guise TA. The role of TGF-β in bone metastasis: novel therapeutic perspectives. Bonekey Rep. 2012;1:1–10.
   PubMedGoogle Scholar
• Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12:159–169.
   PubMed Web of Science ®Google Scholar
• Hiraga T, Myoui A, Hashimoto N, et al. Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res. 2012;72:4238–4249.
   PubMed Web of Science ®Google Scholar
• Goya M, Miyamoto S, Nagai K, et al. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res. 2004;64:6252–6258.
   PubMed Web of Science ®Google Scholar
• Logan JG, Sophocleous A, Marino S, et al. Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis. J Bone Miner Res. 2013;28:1229–1242.
   PubMed Web of Science ®Google Scholar
• Bowers LW, Rossi EL, O’Flanagan CH, et al. The role of the Insulin/IGF system in cancer: lessons learned from clinical trials and the energy balance-cancer link. Front Endocrinol. 2015;6:77.
   PubMedGoogle Scholar
• Scala S. Molecular pathways: targeting the CXCR4-CXCL12 axis-untapped potential in the tumor microenvironment. Clin Cancer Res. 2015;21:4278–4285.
   PubMed Web of Science ®Google Scholar
• Shiozawa Y, Pienta KJ, Taichman RS. Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors. Clin Cancer Res. 2011;17:5553–5558.
   PubMed Web of Science ®Google Scholar
• Andre F, Xia W, Conforti R, et al. CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist. 2009;14:1182–1188.
   PubMed Web of Science ®Google Scholar
• Richert MM, Vaidya KS, Mills CN, et al. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep. 2009;21:761–767.
   PubMed Web of Science ®Google Scholar
• Gravina GL, Mancini A, Muzi P, et al. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models. Prostate. 2015;75:1227–1246.
   PubMed Web of Science ®Google Scholar
• Ntziachristos P, Lim JS, Sage J, et al. From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell. 2014;25:318–334.
   PubMed Web of Science ®Google Scholar
• Sethi N, Dai X, Winter CG, et al. Tumor-derived Jagged1 promotes osteolytic bone metastasis of breast cancer by engaging Notch signaling in bone cells. Cancer Cell. 2011;19:192–205.
   PubMed Web of Science ®Google Scholar
• Takebe N, Miele L, Harris PJ, et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015;12:445–464.
   PubMed Web of Science ®Google Scholar
• Okazaki M, Takeshita S, Kawai S, et al. Molecular cloning and characterization of OB-cadherin, a new member of cadherin family expressed in osteoblasts. J Biol Chem. 1994;269:12092–12098.
   PubMed Web of Science ®Google Scholar
• Pishvaian MJ, Feltes CM, Thompson P, et al. Cadherin-11 Is expressed in invasive breast cancer cell lines. Cancer Res. 1999;59:947–952.
   PubMed Web of Science ®Google Scholar
• Chu K, Cheng C-J, Ye X, et al. Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res. 2008;6:1259–1267.
   PubMed Web of Science ®Google Scholar
• Huang C-F, Lira C, Chu K, et al. Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Res. 2010;70:4580–4589.
   PubMed Web of Science ®Google Scholar
• Tamura D, Hiraga T, Myoui A, et al. Cadherin-11-mediated interactions with bone marrow stromal/osteoblastic cells support selective colonization of breast cancer cells in bone. Int J Oncol. 2008;33:17–24.
   PubMed Web of Science ®Google Scholar
• Lee Y-C, Bilen MA, Yu G, et al. Inhibition of cell adhesion by a cadherin-11 antibody thwarts bone metastasis. Mol Cancer Res. 2013;11:1401–1411.
   PubMed Web of Science ®Google Scholar
• Lee RJ, Smith MR. Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer. Cancer J. 2013;19:90–98.
   PubMed Web of Science ®Google Scholar
• Dai J, Zhang H, Karatsinides A, et al. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clin Cancer Res. 2014;20:617–630.
   PubMed Web of Science ®Google Scholar
• Nguyen HM, Ruppender N, Zhang X, et al. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One. 2013;8:1–15.
   Google Scholar
• Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013;31:412–419.
   PubMed Web of Science ®Google Scholar
• Pichler M, Calin GA. MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients. Br J Cancer. 2015;113:569-573.
   PubMed Web of Science ®Google Scholar
• Croset M, Kan C, Clézardin P. Tumour-derived miRNAs and bone metastasis. Bonekey Rep. 2015;4:688.
   PubMedGoogle Scholar
• Ell B, Mercatali L, Ibrahim T, et al. Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell. 2013;24:542–556.
   PubMed Web of Science ®Google Scholar
• Balic M, Lin H, Young L, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res. 2006;12:5615–5621.
   PubMed Web of Science ®Google Scholar
• Hiraga T, Ito S, Nakamura H. Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res. 2013;73:4112–4122.
   PubMed Web of Science ®Google Scholar
• Plaks V, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell. 2015;16:225–238.
   PubMed Web of Science ®Google Scholar
• Yoneda T, Tanaka S, Hata K. Role of RANKL/RANK in primary and secondary breast cancer. World J Orthop. 2013;4:178–185.
   PubMedGoogle Scholar